Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Reexamination Certificate
2003-12-16
2010-12-21
McGarry, Sean (Department: 1635)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
C536S023100, C536S024300, C536S024330, C536S024500
Reexamination Certificate
active
07855183
ABSTRACT:
The present invention is directed to the use of bcl-2 antisense oligomers to treat and prevent bcl-2 related disorders. These disorders include cancers, tumors, carcinomas and cell-proliferative related disorders. In one embodiment of the invention, a bcl-2 antisense oligomer is administered at high doses. The present invention is also directed to a method of preventing or treating a bcl-2 related disorder, in particular cancer, comprising administering a bcl-2 antisense oligomer for short periods of time. The present invention is further drawn to the use of bcl-2 antisense oligomers to increase the sensitivity of a subject to cancer therapeutics. The present invention also relates to pharmaceutical compositions comprising one or more bcl-2 antisense oligomers, which may comprise one or more cancer therapeutic agents.
REFERENCES:
patent: 5831066 (1998-11-01), Reed
patent: 6040181 (2000-03-01), Reed
patent: 6214986 (2001-04-01), Bennett et al.
patent: 2004/0147473 (2004-07-01), Warrell, Jr.
Webb et al., 1997. BCL-2 antisense therapy in patients with non-Hodgkin lymphoma. The Lancet, vol. 349:1137-1141.
Waters et al., 2000. Phase I clinical and pharmacokinetic study of BcI-2 antisense oigonucleotide therapy in patients with non-Hodgkin's lymphoma. Journal of Clinical Oncology, vol. 18:1812-1823.
Cotter et al., 1994. Antisense oligonucleotides suppress B-cell lymphoma growth in a SCID-hu mouse model. Oncogene, vol. 9:3049-3055.
Morris et al. A Phase I/IIA Dose-Escalating Trial of bcl-2 antisense (G3139) treatment by 14-day continuous intravenous infusion (CI) for patients with androgen-independent prostate cancer or other advanced solid tumor malignancies. Proceedings of the American Society of Clinical Oncology, 1999 vol. 18:323a.
Okamoto et al. Phase II study of area under the palsma-concentration-versus-time curve-based carboplatin plus standard-dose instravenous etoposide in elderly patients with small-cell lung cancer. Journal of Clinical Oncology, 1999 vol. 17:3540-3545.
Kaye et al. Phase II trials of docetaxel (taxotere) in advanced ovarian cancer-an updated overview. European Journal of Cancer, 1997 vol. 33:2167-2170.
Czuczman et al. Treatment of patients with low-grade B-cell lymphoma with the combination of chimeric anti-CD20 monoclonal antibody and CHOP chemotherapy. Journal of Clinical Oncology, 1999 vol. 17:268-276.
Atienza et al. Phase II study of oral etoposide for patients with advanced breast cancer. Cancer, 1995 vol. 76:2485-2490.
Ettinger, DS, Oncology, Jan. 1998, (Suppl 2):36-43. The role of carboplatin in the treatment of small-cell lung cancer.
Furuse, K, Oncology, 1992 (Suppl 49):63-69. Platinum/oral etoposide therapy in non-small cell lung cancer.
Zangemeister et al. Clinical Cancer Research, 2000 vol. 6:2547-2555.
Chi. Kim et al., “A Phase I Trial of an Antisense Oligonucleotide to BCL-2 (G3139, Genta) and Mitoxantrone in Patients with Metastatic Hormone Refractory Prostate Cancer (HRPC)” Meeting: 2000 ASCO Annual Meeting, Abs. No. 1299, p. 1.
Chi, Kim N. et al., “A Phase I Dose-finding Study of Combined Treatment with an Antisense Bcl-2 Oligonucleotide (Genasense) and Mitoxantrone in Patients with Metastatic Hormone-refractory Prostate Cancer” Clinical Cancer Research Dec. 2001 vol. 7; 3920-3927.
Banerjee, Debabrata, Genasense Genta Inc., Current Opinion in Investigational Drugs 2001 2(4) 574-580.
Chen, Helen, et al., “A Phase I Study of BCL-2 Antisense G3139 (GENTA) and Weekly Docetaxel in Patients with Advanced Breast Cancer and Other Solid Tumors” Meeting: 2000 ASCO Annual Meeting, Abs. No. 692, p. 1.
Scher, Howard, et al., “A Phase I Trial of G3139 (Genta. Inc.), a BCL-2 Antisense Drug, by Continuous Infusion (CI) as a Single Agent and with Weekly Taxol (T)” Meeting: 2000 ASCO Annual Meeting, Abs. No. 774, p. 1.
Jansen, B. et al., “Chemosensitisation of malignant melanoma by BCL-2 antisense therapy”, Early Report: The Lancet, vol. 356, (Nov. 18, 2000), pp. 1728-1733.
McLaughlin, P. et al. “Rituximab Chimeric Anti-CD20 Monoclonal Antibody Therapy for Relapsed Indolent Lymphoma: Half of Patients Respond to a Four-Dose Treatment Program”, J. of Clinical Oncology, vol. 16:8 (Aug. 1998) pp. 2825-2833.
Diehl Servilla LLC
Genta Incorporated
Gibbs Terra Cotta
McGarry Sean
LandOfFree
Methods of treatment of a bcl-2 disorder using bcl-2... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods of treatment of a bcl-2 disorder using bcl-2..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods of treatment of a bcl-2 disorder using bcl-2... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4232063